Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Emmanuel Nicolini

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Blood|January 14, 2017
CML stem cells: evasion for better invasionFranck Emmanuel Nicolini
Oncotarget|June 24, 2017
T315I+ tyrosine-kinase independent CML cells resistanceFranck Emmanuel Nicolini, Elodie Grockowiak, Véronique Maguer-Satta
Bulletin Du Cancer|May 13, 2014
[Professor John M. Goldman 1938-2013]François-Xavier Mahon, Josy Reiffers, Franck Emmanuel Nicolini
Bulletin Du Cancer|June 20, 2022
[French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia]Delphine Réa, Emmanuel Messas, Tristan Mirault, et al.
Bulletin Du Cancer|October 30, 2007
[Treatment of chronic myeloid leukemia in 2007]Hélène Labussière, Sandrine Hayette, Isabelle Tigaud, et al.
Expert Review of Hematology|July 10, 2023
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemiaFrançoise Huguet, Delphine Réa, Emilie Cayssials, et al.
Bulletin Du Cancer|August 6, 2011
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia]Marine Demarquet, Hélène Labussière-Wallet, Emmanuelle Nicolas-Virelizier, et al.
Haematologica|January 26, 2006
The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinibFranck Emmanuel Nicolini, Kaddour Chabane, Jean-Michel Cayuela, et al.
Cancers|August 26, 2023
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I MutationFranck-Emmanuel Nicolini, Françoise Huguet, Lynn Huynh, et al.
Experimental Hematology|February 26, 2018
The BMP pathway: A unique tool to decode the origin and progression of leukemiaFlorence Zylbersztejn, Mario Flores-Violante, Thibault Voeltzel, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Blood|January 14, 2017
CML stem cells: evasion for better invasionFranck Emmanuel Nicolini
Oncotarget|June 24, 2017
T315I+ tyrosine-kinase independent CML cells resistanceFranck Emmanuel Nicolini, Elodie Grockowiak, Véronique Maguer-Satta
Bulletin Du Cancer|May 13, 2014
[Professor John M. Goldman 1938-2013]François-Xavier Mahon, Josy Reiffers, Franck Emmanuel Nicolini
Bulletin Du Cancer|June 20, 2022
[French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia]Delphine Réa, Emmanuel Messas, Tristan Mirault, et al.
Bulletin Du Cancer|October 30, 2007
[Treatment of chronic myeloid leukemia in 2007]Hélène Labussière, Sandrine Hayette, Isabelle Tigaud, et al.
Expert Review of Hematology|July 10, 2023
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemiaFrançoise Huguet, Delphine Réa, Emilie Cayssials, et al.
Bulletin Du Cancer|August 6, 2011
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia]Marine Demarquet, Hélène Labussière-Wallet, Emmanuelle Nicolas-Virelizier, et al.
Haematologica|January 26, 2006
The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinibFranck Emmanuel Nicolini, Kaddour Chabane, Jean-Michel Cayuela, et al.
Cancers|August 26, 2023
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I MutationFranck-Emmanuel Nicolini, Françoise Huguet, Lynn Huynh, et al.
Experimental Hematology|February 26, 2018
The BMP pathway: A unique tool to decode the origin and progression of leukemiaFlorence Zylbersztejn, Mario Flores-Violante, Thibault Voeltzel, et al.
Pageof 7